TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22421192

Group type: EXPERIMENTAL
Intervention: Regorafenib (160 mg daily, administered orally for 21 days on/seven days off in repeating cycles)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Regorafenib (160 mg daily)
Number of subjects: 53
Study: 22421222

Group type: EXPERIMENTAL
Intervention: Nonculprit lesions with plaque burden ≥ 70%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonculprit lesions with minimal luminal area ≤ 4.0 mm²
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonculprit lesions with IVUS-VH phenotype of thin-cap fibroatheroma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cumulative rate of major adverse cardiovascular events
Number of subjects: 0
Study: 22421223

Group type: EXPERIMENTAL
Intervention: Proximal segments
Number of subjects: 4234

Group type: EXPERIMENTAL
Intervention: Mid segments
Number of subjects: 4234

Group type: EXPERIMENTAL
Intervention: Distal segments
Number of subjects: 4234

Group type: COMPARATOR
Intervention: Left Main Coronary Artery (LMCA)
Number of subjects: 4234
Study: 22421227

Group type: EXPERIMENTAL
Intervention: Palpography and intravascular ultrasound virtual histology
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Palpography
Number of subjects: 114

Group type: COMPARATOR
Intervention: Standard treatment (stents and pharmacotherapy)
Number of subjects: 114
Study: 22421228

Group type: EXPERIMENTAL
Intervention: MSCT (multislice computed tomography)
Number of subjects: 32
Study: 22421230

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Met Syn
Number of subjects: 673

Group type: COMPARATOR
Intervention: Neither diabetes nor Met Syn
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Diabetes and Met Syn
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Diabetes and Met Syn with future MACE
Number of subjects: 673
Study: 22421231

Group type: EXPERIMENTAL
Intervention: CKD patients
Number of subjects: 646
Study: 22421232

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 697

Group type: COMPARATOR
Intervention: Men
Number of subjects: 697
Study: 22421234

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS)
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Patients with PB70 lesions
Number of subjects: 697

Group type: COMPARATOR
Intervention: Non-PB70 lesions
Number of subjects: 697
Study: 22421235

Group type: EXPERIMENTAL
Intervention: 1 NC lesion
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: ≥ 2 NC lesions
Number of subjects: 697

Group type: COMPARATOR
Intervention: No NC lesions
Number of subjects: 697
Study: 22421236

Group type: EXPERIMENTAL
Intervention: Nonculprit lesions with substantial lesion progression (SLP)
Number of subjects: 697

Group type: COMPARATOR
Intervention: Nonculprit lesions without substantial lesion progression (SLP)
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Nonculprit lesions with SLP
Number of subjects: 697

Group type: COMPARATOR
Intervention: Nonculprit lesions without SLP
Number of subjects: 697
Study: 22421340

Group type: EXPERIMENTAL
Intervention: IL6R SNP (rs7529229)
Number of subjects: 133449

Group type: COMPARATOR
Intervention: Tocilizumab (4-8 mg/kg every 4 weeks)
Number of subjects: 133449
Study: 22421626

Group type: EXPERIMENTAL
Intervention: 10 meter walking test
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 6 minute walk test
Number of subjects: 132

Group type: COMPARATOR
Intervention: Healthy controls (10 meter walking test)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Healthy controls (6 minute walk test)
Number of subjects: 132
Study: 22422792

Group type: EXPERIMENTAL
Intervention: Pharmaceutical thrombosis prophylaxis (PTP) with low-molecular-weight heparin (LMWH)
Number of subjects: 5297
Study: 22422826

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 25 mg orally twice a day for 4 weeks (1 cycle), with dose escalation to 50 mg twice daily permitted for patients showing benefit.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 38
Study: 22423615

Group type: EXPERIMENTAL
Intervention: Intensity-modulated and image-guided radiotherapy (IMRT-IGRT) by helical tomotherapy, delivering a dose of 50 Gy in fractions of 5 Gy.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Helical tomotherapy delivering 10 fractions of 5 Gy.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Helical tomotherapy
Number of subjects: 24
Study: 22424004

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Collaborative quality initiatives including radiation dose reduction and appropriate CCTA use
Number of subjects: 47
Study: 22424178

Group type: EXPERIMENTAL
Intervention: Low frequency ultrasound (LFU)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Salbutamol (short-acting bronchodilator)
Number of subjects: 26
Study: 22424246

Group type: EXPERIMENTAL
Intervention: Lab-based risk score
Number of subjects: 122270

Group type: EXPERIMENTAL
Intervention: BMI-based risk score
Number of subjects: 122270

Group type: EXPERIMENTAL
Intervention: Concordance between lab-based and BMI-based risk scores
Number of subjects: 122270

Group type: EXPERIMENTAL
Intervention: BMI-based risk score vs lab-based risk score
Number of subjects: 122270

Group type: EXPERIMENTAL
Intervention: Concordance among lower estimated risk individuals
Number of subjects: 122270
Study: 22424880

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1953
Study: 22425095

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg with continuous daily dosing
Number of subjects: 30
Study: 22425822

Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia 1 xenon (70% for 1 hr)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mild therapeutic hypothermia (33°C for 16 hrs)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normothermic controls
Number of subjects: 15
Study: 22426369

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H1N1 influenza vaccine (3.75µg HA)
Number of subjects: 100
Study: 22426890

Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination with IL-2, Cyclophosphamide, and Celecoxib
Number of subjects: 28
Study: 22427378

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day
Number of subjects: 200
Study: 22427577

Group type: EXPERIMENTAL
Intervention: RVM analyses of baseline CSLO parameters
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: RVM analyses of baseline SAP parameters
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: RVM analyses of baseline CSLO and SAP parameters combined
Number of subjects: 264

Group type: COMPARATOR
Intervention: CSLO Glaucoma Probability Score
Number of subjects: 264

Group type: COMPARATOR
Intervention: SAP mean deviation (MD)
Number of subjects: 264

Group type: COMPARATOR
Intervention: SAP pattern standard deviation (PSD)
Number of subjects: 264
Study: 22427678

Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 93
Study: 22427705

Group type: EXPERIMENTAL
Intervention: VHX trial (NCT01074905)
Number of subjects: 0
Study: 22428786

Group type: EXPERIMENTAL
Intervention: High urinary phthalate concentration (measured as quartiles of phthalate metabolites)
Number of subjects: 725
Study: 22429873

Group type: EXPERIMENTAL
Intervention: Inpatient weight-loss program for children and adolescents (4 to 6 weeks duration) focusing on diet, physical activity, and behavior therapy.
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Inpatient weight-loss program follow-up assessments at 6 months, 1, 2, 5, and 10 years.
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Blood parameters and exercise capacity measurements at 5 and 10 year follow-ups.
Number of subjects: 1500
Study: 22429908

Group type: COMPARATOR
Intervention: No anticoagulants
Number of subjects: 1074

Group type: EXPERIMENTAL
Intervention: Symptomatic SVT patients
Number of subjects: 1074

Group type: EXPERIMENTAL
Intervention: Patients with cancer or saphenofemoral junction involvement
Number of subjects: 1074

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 1074
Study: 22430088

Group type: EXPERIMENTAL
Intervention: MRD-positive patients before UCBT
Number of subjects: 143

Group type: COMPARATOR
Intervention: MRD-negative patients before UCBT
Number of subjects: 143
Study: 22430246

Group type: EXPERIMENTAL
Intervention: Fluid-balance-adjusted body mass index categorized as overweight
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Fluid-balance-adjusted body mass index categorized as obese
Number of subjects: 580
Study: 22431570

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (GA101) administered in a dose-escalating fashion (3 per cohort, range 50/100-1200/2000 mg) for 8 × 21-day cycles
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (GA101)
Number of subjects: 21
Study: 22431702

Group type: EXPERIMENTAL
Intervention: PLD plus carboplatin (Arm 1a)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: PLD plus carboplatin (Arm 1b)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: PLD plus carboplatin + Herceptin (Arm 2)
Number of subjects: 129
Study: 22431777

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Untreated tumors
Number of subjects: 1
Study: 22432117

Group type: EXPERIMENTAL
Intervention: Dopamine type 2 receptor (D2R) availability measured using positron emission tomography and [(18)F]fallypride
Number of subjects: 22
Study: 22432687

Group type: EXPERIMENTAL
Intervention: Cognitex supplementation (3 capsules per day for 12 weeks)
Number of subjects: 30
Study: 22433615

Group type: EXPERIMENTAL
Intervention: Behavioral obesity treatment
Number of subjects: 684
Study: 22434211

Group type: EXPERIMENTAL
Intervention: Diagnostic vitrectomy
Number of subjects: 150
Study: 22434595

Group type: EXPERIMENTAL
Intervention: Assisted reproductive technology (ART)
Number of subjects: 65
Study: 22434735

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) counselling sessions with a parent of the index child in Year 1 and one additional 'booster' visit in Year 2.
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Six MI counselling sessions from a trained dietician.
Number of subjects: 633

Group type: COMPARATOR
Intervention: Usual care (standard health education materials).
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Parent report of child's screen time, physical activity, intake of fruits and vegetables, and sugar-sweetened beverages.
Number of subjects: 633
Study: 22436147

Group type: EXPERIMENTAL
Intervention: ART prescribed between baseline and 2 months
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: ART prescribed between 2 and 5 months
Number of subjects: 1605

Group type: COMPARATOR
Intervention: PTB patients
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: HIV infected patients not receiving ART
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: HIV infected patients already on ART at baseline
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: PTB patients (overall)
Number of subjects: 1605

Group type: COMPARATOR
Intervention: Non-TB controls
Number of subjects: 1605
Study: 22436661

Group type: EXPERIMENTAL
Intervention: H-1PV by intratumoral injection and administration into the walls of the tumor cavity during tumor resection
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: H-1PV injected intravenously and into the surrounding brain tissue during tumor removal
Number of subjects: 18
Study: 22437560

Group type: EXPERIMENTAL
Intervention: Dietary protein intake (percentage energy)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Milk intake (L/d)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Android fat:gynoid fat ratio
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Android fat:body fat ratio
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Gynoid fat:body fat ratio
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Pedometer counts
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: HOMA
Number of subjects: 182
Study: 22437872

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies (mAbs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibody-drug conjugates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunomodulatory antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic antibodies
Number of subjects: 0
Study: 22438225

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program (exercise, behavior, and nutrition therapy) for 1 year
Number of subjects: 100

Group type: COMPARATOR
Intervention: Obese children
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Obese children with and without MetS or NAFLD
Number of subjects: 100
Study: 22438229

Group type: EXPERIMENTAL
Intervention: Alipogene tiparvovec (AAV1-LPL(S447X)), administered at a dose of 1 × 10(12) genome copies per kilogram, intramuscularly.
Number of subjects: 0
Study: 22438256

Group type: EXPERIMENTAL
Intervention: Obinutuzumab induction (200-2000 mg IV weekly for 4 weeks) followed by maintenance every 3 months for a maximum of 8 doses
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Obinutuzumab maintenance therapy
Number of subjects: 22
Study: 22438931

Group type: EXPERIMENTAL
Intervention: Anakinra (IL-1 receptor antagonist)
Number of subjects: 7
Study: 22438987

Group type: EXPERIMENTAL
Intervention: Sublingual (SL) administration of quadravalent HPV vaccine (n = 12)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intramuscular (IM) administration of quadravalent HPV vaccine (n = 6)
Number of subjects: 18
Study: 22439666

Group type: EXPERIMENTAL
Intervention: Cetuximab (single agent treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Folfiri-cetuximab regimen (after initial treatment with cetuximab)
Number of subjects: 0
Study: 22439900

Group type: EXPERIMENTAL
Intervention: Ambulatory heart rate
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Ambulatory heart rate variability
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Clinical heart rate
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Night/day systolic blood pressure ratio
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 360
Study: 22440484

Group type: EXPERIMENTAL
Intervention: Lower EROS scores (Environment Rewards Observation Scale)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Lower self-efficacy (Modified Lorig Chronic Disease Self-Management Scale)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Physical activity (International Physical Activity Questionnaire)
Number of subjects: 244
Study: 22440496

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 5011
Study: 22441650

Group type: EXPERIMENTAL
Intervention: MVA-NP+M1 vaccine
Number of subjects: 22

Group type: COMPARATOR
Intervention: No vaccination (control)
Number of subjects: 22
Study: 22442048

Group type: EXPERIMENTAL
Intervention: Square area measurements of orbital apex crowding calculated with multidetector CT (MDCT)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: CIs at 12 mm, 18 mm, and 24 mm
Number of subjects: 56

Group type: COMPARATOR
Intervention: Subjective grading of orbital crowding
Number of subjects: 56

Group type: COMPARATOR
Intervention: Intracranial fat prolapse
Number of subjects: 56
Study: 22442161

Group type: EXPERIMENTAL
Intervention: Colonoscopy by experienced colonoscopists with varying CME meetings attended
Number of subjects: 12134

Group type: EXPERIMENTAL
Intervention: Colonoscopy by colonoscopists with different instrument generations used
Number of subjects: 12134

Group type: EXPERIMENTAL
Intervention: Colonoscopy with varying annual CME meetings attended by physicians
Number of subjects: 12134

Group type: EXPERIMENTAL
Intervention: Colonoscopy with withdrawal times between 6-11 minutes
Number of subjects: 12134

Group type: EXPERIMENTAL
Intervention: Colonoscopy with varying annual screening case volumes
Number of subjects: 12134
Study: 22442346

Group type: EXPERIMENTAL
Intervention: Molecular complete response (CR) after consolidation chemotherapy
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Molecular failure without stem cell transplantation (SCT) in first CR
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Quantitative MRD assessment
Number of subjects: 580
Study: 22443231

Group type: EXPERIMENTAL
Intervention: 5 mL ropivacaine 0.75%
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 20 mL ropivacaine 0.75%
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 10 mL ropivacaine 0.75%
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 36
Study: 22443293

Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release (50-250 mg bid) during a 5-week titration and 7-week maintenance period.
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release treatment for patients with neuropathic pain component.
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release overall.
Number of subjects: 175
Study: 22443344

Group type: EXPERIMENTAL
Intervention: Malaria Rapid Diagnostic Tests (RDTs)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 190

Group type: COMPARATOR
Intervention: Polymerase Chain Reaction (PCR)
Number of subjects: 190
Study: 22443802

Group type: EXPERIMENTAL
Intervention: Neoadjuvant short course intensity-modulated radiation therapy (5 × 5 Gy) and intraoperative radiation therapy (15 Gy)
Number of subjects: 46
Study: 22445005

Group type: EXPERIMENTAL
Intervention: Gamma Knife stereotactic radiosurgery (SRS) boost to areas of high risk determined by magnetic resonance spectroscopy (MRS) functional imaging in addition to standard radiotherapy.
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Gamma Knife stereotactic radiosurgery (SRS) boost with standard radiotherapy.
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Concurrent temozolomide with protocol radiotherapeutic treatment.
Number of subjects: 35

Group type: COMPARATOR
Intervention: Radiotherapy alone (historical control).
Number of subjects: 35

Group type: COMPARATOR
Intervention: Radiotherapy and temozolomide (historical control).
Number of subjects: 35
Study: 22446154

Group type: EXPERIMENTAL
Intervention: Four-month daily pelvic floor muscle (PFM) strengthening exercise program at home
Number of subjects: 68
Study: 22447794

Group type: EXPERIMENTAL
Intervention: qPCR-positive for P. falciparum in peripheral and/or placental blood samples
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: qPCR-positive placental infections
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: qPCR-positive but negative in peripheral blood by microscopy or HRP2 RDT in plasma
Number of subjects: 272
Study: 22447793

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 480
Study: 22447809

Group type: EXPERIMENTAL
Intervention: Sildenafil (40 or 80 mg)
Number of subjects: 20
Study: 22447863

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the retina using a group of 2 × 2 adjacent electrodes at upper comfortable stimulation amplitude
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Changing stimulation pulse rate
Number of subjects: 9
Study: 22448814

Group type: EXPERIMENTAL
Intervention: BCX1777 (forodesine) 100 mg/day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: BCX1777 (forodesine) 200 mg/day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: BCX1777 (forodesine) 300 mg/day
Number of subjects: 13
Study: 22448921

Group type: EXPERIMENTAL
Intervention: Combotox (low-dose) + Cytarabine (Ara-C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combotox (high-dose) + Cytarabine (Ara-C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential administration of Ara-C and Combotox
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concurrent administration of Ara-C and Combotox
Number of subjects: 0
Study: 22448928

Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injection (RLAI)
Number of subjects: 784
Study: 22449204

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of aspirin and heparin
Number of subjects: 0
Study: 22449224

Group type: COMPARATOR
Intervention: Conventional vestibular rehabilitation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Virtual reality based vestibular rehabilitation (Nintendo Wii Fit Plus®)
Number of subjects: 80
Study: 22450529

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided TAP blocks with bilateral injections of 20 ml ropivacaine 0.5% w/v (total dose 200 mg)
Number of subjects: 21
Study: 22450943

Group type: EXPERIMENTAL
Intervention: More frequent chocolate consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 22451421

Group type: EXPERIMENTAL
Intervention: Recombinant factor XIII (rFXIII) prophylaxis
Number of subjects: 41
Study: 22451423

Group type: EXPERIMENTAL
Intervention: Combination of bendamustine (75 mg/m² on days 1 and 2), lenalidomide (10 mg on days 1-21), and dexamethasone (40 mg weekly) in a 28-day cycle
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combination of bendamustine, lenalidomide, and dexamethasone
Number of subjects: 29
Study: 22452895

Group type: EXPERIMENTAL
Intervention: Afatinib 50 mg daily
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg daily
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 129
Study: 22453048

Group type: EXPERIMENTAL
Intervention: Mild stunting
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Moderate-severe stunting
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Mild underweight
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Moderate-severe underweight
Number of subjects: 351
Study: 22453570

Group type: EXPERIMENTAL
Intervention: Invasive strategy (systematic electrophysiological studies and prophylactic permanent pacing)
Number of subjects: 486

Group type: COMPARATOR
Intervention: Noninvasive strategy
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 486
Study: 22454801

Group type: EXPERIMENTAL
Intervention: Aripiprazole (15-30 mg/d)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Lithium (900-1500 mg/d)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study: 22455454

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 150 mg eq (234 mg) administered via deltoid injection, with subsequent once-monthly injections of the same dose.
Number of subjects: 212